MedPath

Postoperative subQ Pain Control for Spinal Fusion Surgery

Phase 2
Completed
Conditions
Spine Fusion
Surgery
Pain, Postoperative
Interventions
Drug: 0.25% Marcaine at 2ml/hr and pain medications
Device: Placement of OnQ Drug pump
Registration Number
NCT03476811
Lead Sponsor
University of Arizona
Brief Summary

Post-operative pain following lumbar spine fusion is frequently difficult to manage and can lead to increased doses of opiate pain medications to control pain. In this study, the use of subcutaneous local anesthesia will be studied to determine its efficacy at reducing post-operative pain following spinal fusion surgery.

Detailed Description

For patients randomized to the experimental or to the placebo groups, two subcutaneous catheters will be tunneled under the skin with large hollow-bore needles along the entire length of the incision on either side prior to closure. These catheters will deliver study drug (0.25% Marcaine) directly into the incision. They will be affixed to the skin with steri-strips. The catheters will then be attached to a drug delivery pump at 2mL/hour and will be removed prior to discharge.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
11
Inclusion Criteria
  • Patient 18 years of age or greater
  • Surgery to be done at Banner University Medical Center-Tucson
  • Elective Surgeries only
  • Lower Thoracic or Lumbar fusions only - Posterior Approach
  • Postero or Posterolateral Instrumented Fusions with or without Interbody graft
  • Transforaminal Interbody Fusions
  • Must be able to cooperate in the daily VAS assessment
Exclusion Criteria
  • Patients under 18 years of age
  • Prisoners
  • Pregnant women
  • Hypersensitivity to infusion medication
  • Deformity Correction cases requiring osteotomies
  • Surgical fusion in acute phase for traumatic injury
  • Anterior Lumbar Interbody Fusion, Direct Lateral Interbody Fusion procedures

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Marciano Group0.25% Marcaine at 2ml/hr and pain medicationsSubcutaneous pain control with OnQ pump (0.25% Marcaine at 2ml/hr) and pain medications.
Placebo GroupPlacement of OnQ Drug pumpOnQ pump with placebo (normal saline at 2ml/hr) and pain medications.
Primary Outcome Measures
NameTimeMethod
Pain controlFrom post operative day 1 until patient discharge or 30 days, whichever comes first

A daily Visual Analog Score Pain scale (1-10) for pain severity, (1 least pain, 10 most pain) will be assessed and recorded daily by a blinded assessor.

Secondary Outcome Measures
NameTimeMethod
Time to dischargefrom the day of hospital admission to the day of hospital discharge or 45 days, whichever comes first.

Number of hospital days from time when patient surgery is completed to discharge will be assessed

Total Milligrams of IV pain medicationfrom the first post-operative dose of IV pain medication until the last dose prior to discharge from the hospital or 45 days, whichever comes first

Total milligrams of IV pain medications will be assessed

Total Doses of IV pain medicationfrom the first post-operative dose of IV pain medication until the last dose prior to discharge from the hospital or 45 days, whichever comes first

Number of doses of IV pain medications will be assessed

Total Milligrams of oral pain medicationfrom the first post-operative dose of oral pain medication until the last dose prior to discharge from the hospital or 45 days, whichever comes first

Total milligrams of oral pain medications will be assessed

Total Doses of oral pain medicationfrom the first post-operative dose of oral pain medication until the last dose prior to discharge from the hospital or 45 days, whichever comes first

Total doses of oral pain medications will be assessed

Trial Locations

Locations (1)

The University of Arizona

🇺🇸

Tucson, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath